BlackRock Amends Regeneron Stake; Passive Investment Update

TL;DR

**BlackRock just updated its Regeneron stake, showing its latest passive investment position.**

AI Summary

BlackRock Inc. filed an amended Schedule 13G/A on January 25, 2024, indicating a change in its ownership of Regeneron Pharmaceuticals Inc. common stock as of December 31, 2023. This filing, Amendment No. 14, shows BlackRock's updated passive investment stake in the pharmaceutical company. This matters to investors because BlackRock is a major institutional investor, and changes in its holdings can signal shifts in confidence or strategy regarding Regeneron's future performance.

Why It Matters

This filing updates BlackRock's passive ownership in Regeneron, providing transparency on a major institutional investor's position, which can influence market perception.

Risk Assessment

Risk Level: low — This is a routine update from a passive institutional investor and does not indicate any immediate significant risk or opportunity.

Analyst Insight

Investors should note BlackRock's continued passive interest in Regeneron, but this filing alone doesn't suggest a need for immediate action. It's a routine update reflecting a large institutional holder's position.

Key Players & Entities

• BlackRock Inc. (company) — filer of the SC 13G/A
• REGENERON PHARMACEUTICALS, INC. (company) — subject company of the filing
• December 31, 2023 (date) — date of event requiring the filing
• January 25, 2024 (date) — filing date of the SC 13G/A

FAQ

From the Filing

0001086364-24-003704.txt : 20240125 0001086364-24-003704.hdr.sgml : 20240125 20240125165923 ACCESSION NUMBER: 0001086364-24-003704 CONFORMED SUBMISSION TYPE: SC 13G/A PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 20240125 DATE AS OF CHANGE: 20240125 SUBJECT COMPANY: COMPANY DATA: COMPANY CONFORMED NAME: REGENERON PHARMACEUTICALS, INC. CENTRAL INDEX KEY: 0000872589 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 133444607 STATE OF INCORPORATION: NY FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: SC 13G/A SEC ACT: 1934 Act SEC FILE NUMBER: 005-41938 FILM NUMBER: 24562893 BUSINESS ADDRESS: STREET 1: 777 OLD SAW MILL RIVER ROAD CITY: TARRYTOWN STATE: NY ZIP: 10591 BUSINESS PHONE: 9148477000 MAIL ADDRESS: STREET 1: 777 OLD SAW MILL RIVER ROAD CITY: TARRYTOWN STATE: NY ZIP: 10591 FORMER COMPANY: FORMER CONFORMED NAME: REGENERON PHARMACEUTICALS INC DATE OF NAME CHANGE: 19930328 FILED BY: COMPANY DATA: COMPANY CONFORMED NAME: BlackRock Inc. CENTRAL INDEX KEY: 0001364742 STANDARD INDUSTRIAL CLASSIFICATION: SECURITY BROKERS, DEALERS & FLOTATION COMPANIES [6211] ORGANIZATION NAME: 02 Finance IRS NUMBER: 320174431 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: SC 13G/A BUSINESS ADDRESS: STREET 1: 50 HUDSON YARDS CITY: NEW YORK STATE: NY ZIP: 10001 BUSINESS PHONE: 212-810-5300 MAIL ADDRESS: STREET 1: 50 HUDSON YARDS CITY: NEW YORK STATE: NY ZIP: 10001 FORMER COMPANY: FORMER CONFORMED NAME: BlackRock, Inc. DATE OF NAME CHANGE: 20060929 FORMER COMPANY: FORMER CONFORMED NAME: New BlackRock, Inc. DATE OF NAME CHANGE: 20060601 SC 13G/A 1 us75886f1075_012524.txt us75886f1075_012524.txt SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No: 14) REGENERON PHARMACEUTICALS INC -------------------------------------------------------- (Name of Issuer) Common Stock -------------------------------------------------------- (Title of Class of Securities) 75886F107 -------------------------------------------------------- (CUSIP Number) December 31, 2023 -------------------------------------------------------- (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [X] Rule 13d-1(b) [ ] Rule 13d-1(c) [ ] Rule 13d-1(d) *The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page. The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes). CUSIP No. 75886F107 (1)Names of reporting persons. BlackRock, Inc. (2) Check the appropriate box if a member of a group (a) [ ] (b) [X] (3) SEC use only (4) Citizenship or place of organization Delaware Number of shares beneficially owned by each reporting person with: (5) Sole voting power 7824297 (6) Shared voting power 0 (7) Sole dispositive power 8629707 (8) Shared dispositive power 0 (9) Aggregate amount beneficially owned by each reporting person 8629707 (10) Check if the aggregate amount in Row (9) excludes certain shares (11) Percent of class represented by amount in Row 9 8.1% (12) Type of reporting person HC Item 1. Item 1(a) Name of issuer: ----------------------------------------------------------------------- REGENERON PHARMACEUTICALS INC Item 1(b) Address of issuer's principal executive offices: ----------------------------------------------------------------------- 777 OLD SAW MILL RIVER ROAD TARRYTOWN NY 10591 Item 2. 2(a) Name of person filing: -----------------------------------------